This week’s Immunology update highlights regulatory and portfolio shifts, mid- to late-stage clinical progress, dermatology access expansion, and continued investment in autoimmune and rare disease research.
In Today’s Newsletter
Dive deeper
🧬 Biogen to acquire Apellis [1] [US • 31 Mar 2026]
https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio
Context: Biogen agreed to buy Apellis for $41 per share in cash plus contingent value rights tied to SYFOVRE global net sales thresholds.
Key point: The deal adds EMPAVELI and SYFOVRE, which Biogen said generated combined 2025 net product revenue of $689 million, and expands Biogen into nephrology commercial infrastructure.
Implication: Signals pipeline investment and modality expansion.
🧫 Earendil starts Phase IIa dosing for HXN-1001 in ulcerative colitis [2] [US • 02 Apr 2026]
https://www.prnewswire.com/news-releases/earendil-labs-announces-first-patient-dosed-in-a-phase-iia-trial-of-a-half-life-extended-anti-tl1a-antibody-hxn-1001-in-patients-with-ulcerative-colitis-302732675.html
Context: HXN-1001 is a half-life-extended anti-TL1A antibody; the company also said Phase I enrollment in healthy volunteers in Australia has been completed.
Key point: Earendil announced first-patient-dosed in a randomized, placebo-controlled Phase IIa ulcerative colitis study assessing safety, tolerability, PK, and preliminary efficacy.
Implication: May influence prescriber choice and payer reviews pending full data.
🩺 Lupus groups commit $1.9M to early-career investigators [3] [US • 02 Apr 2026]
https://www.prnewswire.com/news-releases/the-lupus-research-alliance-and-rheumatology-research-foundation-commit-1-9m-to-empower-early-career-scientists-302732058.html
Context: The Empowering Lupus Research Partnership will fund five early-career scientists and junior investigators through Foundation-managed awards.
Key point: Lupus Research Alliance and the Rheumatology Research Foundation committed $1.9 million to projects spanning SLE diagnosis, immunometabolism, cardiovascular risk, autoimmunity, and menopause-related questions.
Implication: Signals sustained investment in disease-area research capacity and translational pipeline building.
👶 Napo spotlights crofelemer pediatric intestinal failure program at ELITE PED-GI [4] [UAE • 02 Apr 2026]
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-family-company-napo-pharmaceuticals-co-sponsoring-pedia-1154404
Context: Napo said it is supporting an investigator-initiated proof-of-concept study in pediatric intestinal failure associated with microvillus inclusion disease and short bowel syndrome at Sheikh Khalifa Medical City in Abu Dhabi.
Key point: The company said ongoing crofelemer treatment has continued beyond one year in participating patients, with parenteral support reduction reported in the study and an ESPGHAN 2026 abstract submitted for long-term safety and efficacy.
Implication: May influence prescriber choice and payer reviews pending full data.
🧑⚕️ Priovant begins Phase 2b/3 brepocitinib study in lichen planopilaris [5] [US • 02 Apr 2026]
https://www.dermatologytimes.com/view/phase-2b-3-study-begins-for-lpp-with-brepocitinib
Context: Lichen planopilaris has no FDA-approved therapies, and Priovant described this as its fourth late-stage brepocitinib program.
Key point: Priovant initiated a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with enrollment beginning in March 2026.
Implication: May influence prescriber choice and payer reviews pending full data.
🌞 Almirall expands tirbanibulin access and presents new AAD data [6] [US • 01 Apr 2026]
https://www.dermatologytimes.com/view/almirall-announces-expanded-cvs-caremark-coverage-and-new-clinical-data-for-tirbanibulin-at-aad-2026
Context: Tirbanibulin 1% ointment is marketed as KLISYRI for actinic keratosis; the update combined formulary news with poster data presented at AAD 2026.
Key point: Almirall said CVS Caremark formulary additions may expand commercial access to about 26 million insured patients, while pooled and vehicle-controlled analyses supported lesion reduction, complete clearance, and a tolerability profile consistent with prior studies.
Implication: Introduces access changes that may affect pricing, utilization management, and formulary positioning.
🧪 Bambusa reports Phase 1 MAD data for BBT001 in atopic dermatitis [7] [US • 01 Apr 2026]
https://www.manilatimes.net/2026/04/01/tmt-newswire/pr-newswire/bambusa-therapeutics-presented-positive-results-from-the-phase-1-multiple-ascending-dose-trial-of-bbt001-at-the-2026-american-academy-of-dermatology-aad-annual-meeting/2312674
Context: BBT001 is a long-acting bispecific antibody targeting IL-4Rα and IL-31; data were presented from multiple-ascending-dose cohorts in healthy volunteers.
Key point: Bambusa said Phase 1 multiple-ascending-dose data showed biomarker effects on TARC and pSTAT6, a roughly 33-day half-life, and tolerability across tested doses.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Biogen’s Apellis deal [1] is the clearest portfolio-shaping event in this set, adding marketed complement assets and commercial nephrology capabilities.
- Anti-TL1A competition in inflammatory bowel disease continues to build, and Earendil’s move into Phase IIa puts another program into patient testing [2].
- Dermatology remains active across access, late-stage development, and early biologics, spanning tirbanibulin, brepocitinib, and BBT001 [5][6][7].
- Pediatric and rare-disease development remains a visible theme, including crofelemer in pediatric intestinal failure and brepocitinib in lichen planopilaris [4][5].
- Non-commercial ecosystem funding also matters, with lupus research organizations using targeted grants to support the next investigator cohort [3].
🎬 Watch on YouTube the Top Immunology news from the past two weeks, curated by the LucidQuest team.
📚 View the full Immunology archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
FAQ
What does Biogen gain from acquiring Apellis?
Biogen gains two commercial complement medicines, EMPAVELI and SYFOVRE, plus Apellis’ nephrology-facing commercial capabilities. Biogen said the products generated $689 million in 2025 net product revenue and should support growth outlook expansion [1].
What stage is Earendil’s HXN-1001 program in ulcerative colitis?
HXN-1001 has entered Phase IIa in ulcerative colitis, with first patient dosed. Earendil also said Phase I enrollment in healthy volunteers has been completed in Australia [2].
What exactly was funded in the lupus partnership announcement?
The Lupus Research Alliance and Rheumatology Research Foundation committed $1.9 million to five early-career investigators. Topics include SLE diagnosis and prevention, immunometabolism, cardiovascular risk, UNC93B1-linked autoimmunity, and menopause in SLE [3].
What did Napo report for crofelemer in pediatric intestinal failure?
Napo described continued treatment beyond one year in an investigator-initiated UAE study and said parenteral support reduction has been observed. It also said a long-term safety and efficacy abstract was submitted to ESPGHAN 2026 for consideration [4].
Why is brepocitinib in lichen planopilaris notable?
Lichen planopilaris has no FDA-approved treatments in the source report. Priovant’s seamless Phase 2b/3 start expands brepocitinib into another late-stage autoimmune dermatology setting [5].
What was new on tirbanibulin and BBT001 at AAD 2026?
For tirbanibulin, Almirall paired expanded CVS Caremark coverage with new clinical posters on lesion reduction, clearance, and tolerability [6]. For BBT001, Bambusa presented Phase 1 MAD data highlighting biomarker changes, half-life, and tolerability in healthy volunteers [7].
Entities / Keywords
Biogen (BIIB), Apellis Pharmaceuticals (APLS), EMPAVELI (pegcetacoplan), SYFOVRE, complement C3, nephrology, felzartamab, Earendil Labs, HXN-1001, anti-TL1A antibody, ulcerative colitis, inflammatory bowel disease, Lupus Research Alliance, Rheumatology Research Foundation, systemic lupus erythematosus (SLE), Napo Pharmaceuticals, Jaguar Health, crofelemer, intestinal failure (IF), microvillus inclusion disease (MVID), short bowel syndrome (SBS-IF), Priovant Therapeutics, brepocitinib, lichen planopilaris (LPP), TYK2/JAK1, Almirall, tirbanibulin, KLISYRI, actinic keratosis (AK), CVS Caremark, Bambusa Therapeutics, BBT001, atopic dermatitis (AD), IL-4Rα, IL-31, TARC, pSTAT6
